{"contentid": 488599, "importid": NaN, "name": "Inovio edging forward with COVID-19 vaccine", "introduction": "US biotech Inovio might be behind competitors in the development of a COVID-19 vaccine, but the company has provided a reminder that it is still in the game.", "content": "<p>US biotech Inovio Pharmaceuticals (Nasdaq: INO) might be behind competitors in the development of a COVID-19 vaccine, but the company has provided a reminder that it is still in the game.</p>\n<p>Positive safety, tolerability and immunogenicity data have been announced from Inovio&rsquo;s placebo-controlled and blinded Phase II segment of its Phase II/III clinical trial in the USA, called INNOVATE, to evaluate INO-4800, the company&rsquo;s DNA vaccine candidate.</p>\n<p>The preliminary results show in a larger population than the Phase I study that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.</p>\n<p>Inovio plans to file the preliminary Phase II results and device data with the US Food and Drug Administration (FDA). Following the submission and receipt of the agency&rsquo;s permission to proceed, the company will conduct the Phase III trial.</p>\n<p>It was revealed in April that <a href=\"https://www.thepharmaletter.com/article/inovio-tanks-as-govt-funding-for-covid-19-vaccine-withdrawn\" rel=\"follow\">the US government had pulled the plug on funding</a> for Inovio's Phase III trial for the vaccine, but the company will plough on with the late-stage study, doing so largely outside the USA.</p>\n<p>Laurent Humeau, Inovio&rsquo;s chief scientific officer, said: &ldquo;Our Phase II results validate our initial COVID-19 Phase I results in a larger population, which show that INO-4800 continues to be generally safe, well-tolerated and immunogenic in all studied age groups. The expanded data set enabled a clear dose selection to be made with 2.0mg as the dose for the global Phase III efficacy trial.&rdquo;</p>", "date": "2021-05-11 14:51:00", "meta_title": NaN, "meta_keywords": "Phase, vaccine, Inovio, COVID-, company, INO-, results, trial, edging, reminder, game, development, competitors, biotech, data, Pharmaceuticals, preliminar", "meta_description": "US biotech Inovio might be behind competitors in the development of a COVID-19 vaccine, but the company has provided a reminder that it is still in the game.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-11 14:42:36", "updated": "2021-05-11 15:31:59", "access": NaN, "url": "https://www.thepharmaletter.com/article/inovio-edging-forward-with-covid-19-vaccine", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "inovio_large.png", "image2id": "inovio_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "USA", "company_tag": "Inovio Pharmaceuticals", "drug_tag": "INO-4800", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-11 14:51:00"}